Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EBITDA (2020 - 2025)

Caribou Biosciences has reported EBITDA over the past 6 years, most recently at -$26.5 million for Q4 2025.

  • Quarterly EBITDA rose 26.5% to -$26.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$148.3 million through Dec 2025, changed 0.41% year-over-year, with the annual reading at -$148.3 million for FY2025, 0.41% changed from the prior year.
  • EBITDA was -$26.5 million for Q4 2025 at Caribou Biosciences, up from -$27.5 million in the prior quarter.
  • Over five years, EBITDA peaked at -$9.8 million in Q3 2023 and troughed at -$54.2 million in Q2 2025.
  • The 5-year median for EBITDA is -$27.2 million (2022), against an average of -$28.3 million.
  • Year-over-year, EBITDA crashed 534.63% in 2021 and then surged 63.67% in 2023.
  • A 5-year view of EBITDA shows it stood at -$18.6 million in 2021, then tumbled by 42.22% to -$26.5 million in 2022, then dropped by 26.53% to -$33.5 million in 2023, then fell by 7.55% to -$36.0 million in 2024, then increased by 26.5% to -$26.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EBITDA are -$26.5 million (Q4 2025), -$27.5 million (Q3 2025), and -$54.2 million (Q2 2025).